RESULTS OF LIQUID BIOPSY STUDIES BY NEXT
GENERATION SEQUENCING IN PATIENTS WITH
ADVANCED STAGE NON-SMALL CELL LUNG CANCER:
SINGLE CENTER EXPERIENCE FROM TURKEY
Buyuksimsek M1,*, Togun M2, Oguz Kara I1, Bisgin A3,4, Boga I4, Tohumcuoglu M1,
Ogul A1, Evren Yetisir A1, Sahin B1, Erdem Sumbul H5, Mirili C6
*Corresponding Author: Mahmut Buyuksimsek, M.D., Department of Oncology, Çukurova University
Faculty of Medicine, Sarican, Adana, Turkey. Tel: +90-536-862-20-26. Fax: +90-322-338-70-72.
E-mail: mahmutbuyuksimsek@gmail.com
page: 17
|
|
REFERENCES
1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson
AG. Pathology and Genetics of Tumors of the Lung,
Pleura, Thymus, and Heart, 4th ed. Lyon, France: International
Agency for Research on Cancer Press; 2015.
2. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley
MB, Bernicker EH, et al. Updated molecular testing
guideline for the selection of lung cancer patients
for treatment with targeted tyrosine kinase inhibitors:
Guideline from the college of American Pathologists,
the International Association for the Study of Lung
Cancer, and the Association for Molecular Pathology.
Arch Pathol Lab Med. 2018; 142(3): 321-346.
3. Newman AM, Bratman SV, To J, Wynne JF, Eclov
NC, Modlin LA, et al. An ultrasensitive method for
quantitating circulating tumor DNA with broad patient
coverage. Nat Med. 2014; 20(5): 548-554.
4. Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R,
Balli D, et al. Detection of therapeutically targetable
driver and resistance mutations in lung cancer patients
by next-generation sequencing of cell-free circulating
tumor DNA. Clin Cancer Res. 2016; 22(23): 5772-5782.
5. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman
RB, Banks KC, et al. Utility of genomic assessment
of blood-derived circulating tumor DNA
(ctDNA) in patients with advanced lung adenocarcinoma.
Clin Cancer Res. 2017; 23(17): 5101-5111.
6. Sawada K, Kotani D, Bando H. The clinical landscape
of circulating tumor DNA in gastrointerstinal malignancies.
2018; 8: 263. doi: 10.3389/fonc.2018.00263.
eCol lection 2018.
7. Esposito AR, Pasquale R, Fenizia F, Rachiglio AM,
Roma C, Bergantino F, et al. The role of circulating
free DNA in the management of NSCLC. Expert Rev
Anticancer Ther. 2019; 19(1): 19-28.
8. Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K,
Daga H, et al. Diagnostic accuracy of non invasive
genotyping of EGFR in lung cancer patients by deep
sequencing of plasma cell-free DNA. Clin Chem.
2015; 61(9): 1191-1196.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan
EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously
treated non-small-celllung cancer. N Engl J
Med. 2005; 353(2): 123-132.
10. Thatcher N, Chang A, Parikh P, Rodrigues Pereira
J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best
supportive care in previously treated patients with refractory
advanced non-small-cell lung cancer: Results
from a randomized, placebo controlled, multicentre
study (Iressa Survival Evaluation in Lung Cancer).
Lancet. 2004; 366(9496): 1527-1537.
11. Rosell R, Carcereny E, Gervais R, Vergnenegre A,
Massuti B, Felip E, et al. Erlotinib versus standard
chemotherapy as first line treatment for European
patients with advanced EGFR mutation-positive nonsmall-
cell lung cancer (EURTAC): A multicentre,
open-label, randomised phase 3 trial. Lancet Oncol.
2012; 13(3): 239-246.
12. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon
B, Maki RG, et al. Anaplastic lymphoma kinase inhibition
in nonsmall-cell lung cancer. N Engl J Med.
2010; 363(18): 1693-1703.
13. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse
B, Helland Å, et al. Dabrafenib plus trametinib in patients
with previously untreated BRAFV600E-mutant
metastatic non-small-cell lung cancer: An open-label,
phase 2 trial. Lancet Oncol. 2017; 18(10): 1307-1316.
14. Ettinger DS, Wood DE, Akerley W, Bazhenova LA,
Borghaei H, Camidge DR, et al. Non-small cell lung
cancer, version 6.2015. J Natl Compr Canc Netw.
2015; 13(5): 515-524.
15. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-
Tan J, et al. Detection and dynamic changes
of EGFR mutations from circulating tumor DNA as
a predictor of survival outcomes in NSCLC patients
treated with first-line intercalated erlotinib. Clin Cancer
Res. 2015; 21(14): 3196-3203.
16. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole
R, McWalter G, et al. Gefitinib treatment in EGFR
mutated caucasian NSCLC: Circulating-free tumor
DNA as a surrogate for determination of EGFR status.
J Thorac Oncol. 2014; 9(9): 1345-1353.
17. Reck M, Hagiwara K, Han B, Tjulandin S, Grohé
C, Yokoi T, et al. ctDNA determination of EGFR
mutation status in European and Japanese patients
with advanced NSCLC: The ASSESS study. J Thorac
Oncol. 2016; 11(10): 1682-1689.
18. Dearden S, Stevens J, Wu YL, Blowers D. Mutation
incidence and coincidence in non small-cell lung
cancer: Meta-analyses by ethnicity and histology
(mutMap). Ann Oncol. 2013; 24(9): 2371-2376.
19. Zhang X-C, Wang J, Shao G-G, Wang Q, Qu X, Wang
B, et al. Comprehensive genomic and immunological
characterization of Chinese non-small cell lung
cancer patients. Nat Commun. 2019; 10(1): 1772.
20. Song Z, Wang H, Yu Z, Lu P, Xu C, Chen G, et al.
De novo MET amplification in Chinese patients with
non-small-cell lung cancer and treatment efficacy
with crizotinib: A multicenter retrospective study.
Clin Lung Cancer. 2018; 20(2)): e171-e176.
21. Asao T, Takahashi F, Takahashi K. Resistance to
molecularly targeted therapy in non-small-cell lung
cancer. Respir Investig. 2019; 57(1): 20-26. doi:
10.1016/j.resinv. 2018.09.001. Epub 2018 Oct 4.
22. Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ,
Gowen K, et al. EGFR fusions as novel therapeutic
targets in lung cancer. Cancer Discov. 2016; 6(6):
601-611.
23. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR,
Ramalingam SS, et al. Osimertinib or platinumpemetrexed
in EGFR T790M-positive lung cancer.
N Engl J Med. 2017; 376(7): 629-640.
24. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez
LE, Bronte G, et al. Novel therapeutic strategies for
patients with NSCLC that do not respond to treatment
with EGFR inhibitors. Cancer Treatment Rev. 2014;
40(8): 990-1004.
25. Linda K, Mikael J, Kjell G, Jonas N. Liquid biopsies
in lung cancer — time to implement research
technologies in routine care? Ann Transl Med. 2017;
5(13): 278.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
